AKTS AKTIS ONCOLOGY INC
Health Care · Russell 2000
Next earnings: Thu 12 Nov 2026 · estimated
What 11 analyst firms say about AKTIS ONCOLOGY INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
10 rated views · 11 analyst/firm records · 11 firms
Radar score
- Russell 2000 · Top Picks · 6MStrong · #6 in the index93
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8073
Recent analyst activity · last 90 days
Our tracked history has 7 reports on AKTS from 5 analyst firms in the last 90 days (11 firms in the past year).
Comparing each firm's latest target with its previous one: 2 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Bank of America Securities | Unnamed analyst | Buy | 3 Feb 2026 | 34.00 USD |
| BMO Capital Markets | David Lebowitz | Buy | 18 Aug 2026 | 37.00 USD |
| H.C. Wainwright | Robert Burns | Buy | 2 Jun 2026 | 35.00 USD |
| JPMorgan | Jessica Fye | Buy | 14 Jul 2026 | 33.00 USD |
| Leerink Partners | Asthika Goonewardene | Buy | 21 Jul 2026 | 33.00 USD |
| Oppenheimer | Jeff Jones | Buy | 9 Sep 2026 | 40.00 USD |
| Raymond James | Christopher Raymond | Buy | 15 Jun 2026 | 40.00 USD |
| TD Cowen | Tyler Van Buren | Buy | 3 Feb 2026 | — |
| Wedbush | David Nierengarten | Buy | 2 Oct 2026 | 35.00 USD |
| Weiss Ratings | Unnamed analyst | — | 2 Oct 2026 | — |
| William Blair | Alexandra V Ramsey | Buy | 14 Aug 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:11 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.